BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 37230055)

  • 1. TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC).
    Parisi C; Mahjoubi L; Gazzah A; Barlesi F
    Cancer Treat Rev; 2023 Jul; 118():102572. PubMed ID: 37230055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer.
    Shastry M; Jacob S; Rugo HS; Hamilton E
    Breast; 2022 Dec; 66():169-177. PubMed ID: 36302269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-drug conjugates (ADCs) targeting TROP-2 in lung cancer.
    Belluomini L; Avancini A; Sposito M; Milella M; Rossi A; Pilotto S
    Expert Opin Biol Ther; 2023; 23(11):1077-1087. PubMed ID: 36995069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan.
    Heist RS; Guarino MJ; Masters G; Purcell WT; Starodub AN; Horn L; Scheff RJ; Bardia A; Messersmith WA; Berlin J; Ocean AJ; Govindan SV; Maliakal P; Mudenda B; Wegener WA; Sharkey RM; Goldenberg DM; Camidge DR
    J Clin Oncol; 2017 Aug; 35(24):2790-2797. PubMed ID: 28548889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 'Targeting' Improved Outcomes with Antibody-Drug Conjugates in Non-Small Cell Lung Cancer-An Updated Review.
    Verma S; Breadner D; Raphael J
    Curr Oncol; 2023 Apr; 30(4):4329-4350. PubMed ID: 37185443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan.
    Heist RS; Sands J; Bardia A; Shimizu T; Lisberg A; Krop I; Yamamoto N; Kogawa T; Al-Hashimi S; Fung SSM; Galor A; Pisetzky F; Basak P; Lau C; Meric-Bernstam F
    Cancer Treat Rev; 2024 Apr; 125():102720. PubMed ID: 38502995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan.
    Goldenberg DM; Sharkey RM
    MAbs; 2019; 11(6):987-995. PubMed ID: 31208270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscape.
    Adams E; Wildiers H; Neven P; Punie K
    ESMO Open; 2021 Aug; 6(4):100204. PubMed ID: 34225076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TROPION-Lung08: phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC.
    Levy BP; Felip E; Reck M; Yang JC; Cappuzzo F; Yoneshima Y; Zhou C; Rawat S; Xie J; Basak P; Xu L; Sands J
    Future Oncol; 2023 Jul; 19(21):1461-1472. PubMed ID: 37249038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01.
    Shimizu T; Sands J; Yoh K; Spira A; Garon EB; Kitazono S; Johnson ML; Meric-Bernstam F; Tolcher AW; Yamamoto N; Greenberg J; Kawasaki Y; Zebger-Gong H; Kobayashi F; Phillips P; Lisberg AE; Heist RS
    J Clin Oncol; 2023 Oct; 41(29):4678-4687. PubMed ID: 37327461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.
    Bardia A; Mayer IA; Vahdat LT; Tolaney SM; Isakoff SJ; Diamond JR; O'Shaughnessy J; Moroose RL; Santin AD; Abramson VG; Shah NC; Rugo HS; Goldenberg DM; Sweidan AM; Iannone R; Washkowitz S; Sharkey RM; Wegener WA; Kalinsky K
    N Engl J Med; 2019 Feb; 380(8):741-751. PubMed ID: 30786188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics.
    Ocean AJ; Starodub AN; Bardia A; Vahdat LT; Isakoff SJ; Guarino M; Messersmith WA; Picozzi VJ; Mayer IA; Wegener WA; Maliakal P; Govindan SV; Sharkey RM; Goldenberg DM
    Cancer; 2017 Oct; 123(19):3843-3854. PubMed ID: 28558150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy.
    Goldenberg DM; Sharkey RM
    Expert Opin Biol Ther; 2020 Aug; 20(8):871-885. PubMed ID: 32301634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.
    Bardia A; Mayer IA; Diamond JR; Moroose RL; Isakoff SJ; Starodub AN; Shah NC; O'Shaughnessy J; Kalinsky K; Guarino M; Abramson V; Juric D; Tolaney SM; Berlin J; Messersmith WA; Ocean AJ; Wegener WA; Maliakal P; Sharkey RM; Govindan SV; Goldenberg DM; Vahdat LT
    J Clin Oncol; 2017 Jul; 35(19):2141-2148. PubMed ID: 28291390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer.
    Weiss J; Glode A; Messersmith WA; Diamond J
    Expert Rev Anticancer Ther; 2019 Aug; 19(8):673-679. PubMed ID: 31398063
    [No Abstract]   [Full Text] [Related]  

  • 16. A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC).
    Abuhelwa Z; Alloghbi A; Nagasaka M
    Cancer Treat Rev; 2022 May; 106():102393. PubMed ID: 35472631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tackling metastatic triple-negative breast cancer with sacituzumab govitecan.
    Schreiber AR; Andress M; Diamond JR
    Expert Rev Anticancer Ther; 2021 Dec; 21(12):1303-1311. PubMed ID: 34651524
    [No Abstract]   [Full Text] [Related]  

  • 18. Targeting Trop-2 in cancer: Recent research progress and clinical application.
    Qiu S; Zhang J; Wang Z; Lan H; Hou J; Zhang N; Wang X; Lu H
    Biochim Biophys Acta Rev Cancer; 2023 Jul; 1878(4):188902. PubMed ID: 37121444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial.
    Bardia A; Messersmith WA; Kio EA; Berlin JD; Vahdat L; Masters GA; Moroose R; Santin AD; Kalinsky K; Picozzi V; O'Shaughnessy J; Gray JE; Komiya T; Lang JM; Chang JC; Starodub A; Goldenberg DM; Sharkey RM; Maliakal P; Hong Q; Wegener WA; Goswami T; Ocean AJ
    Ann Oncol; 2021 Jun; 32(6):746-756. PubMed ID: 33741442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-drug conjugates: A promising novel therapeutic approach in lung cancer.
    Desai A; Abdayem P; Adjei AA; Planchard D
    Lung Cancer; 2022 Jan; 163():96-106. PubMed ID: 34942494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.